NSAIDs tied to reduced death after colon cancer

	Tweet

Women who regularly use nonsteroidal anti-inflammatory drugs (NSAIDs) have better survival after a colorectal cancer diagnosis, research indicates.

During 2007, an estimated 112,340 cases of colon cancer and 41,420 cases of rectal cancer were diagnosed in the US, making colorectal cancer the third most common cancer among US men and women.

It’s been shown that regular, long-term use of aspirin or other NSAID—such as ibuprofen or naproxen—reduces the risk of developing colorectal cancer, but, until now, potential survival benefits associated with NSAID use had not been established.

To investigate, Dr. Jason A. Zell, from the University of California, Irvine, and colleagues analyzed data from 621 women in the California Teachers Study with colorectal cancer.

Prior to their diagnosis, roughly 64 percent did not use NSAIDs regularly, 17 percent used them 1 to 6 days per week, and 20 percent reported daily use. Overall, roughly 17 percent of the women had regularly taken NSAIDs for less than 5 years and approximately 18 percent reported regular use extending back 5 years or more.

Zell’s team tracked the women from the date of cancer diagnosis until death or December 31, 2005, which yielded an average follow-up of 3.4 years.

They found that regular NSAID use before colorectal cancer diagnosis (defined as 1 to 3 times per week, 4 to 6 times per week, or daily use) was associated with a 42 percent reduced risk of death from colorectal cancer, compared to no regular NSAID use.

In addition, compared with no regular NSAID use, regular pre-diagnosis use was associated with improved overall survival and regular use for 5 years or more was associated with improved overall survival and survival specific to colorectal cancer.

If confirmed in other studies, these findings may have “important implications” for cancer prevention,” the researchers note in the journal Cancer.

Zell told Reuters Health that several NSAID-based colorectal cancer prevention clinical trials are already in the late stages of development. “It is hoped that these new clinical trials will provide definitive recommendations for colorectal cancer risk reduction among colorectal cancer survivors,” he said.

SOURCE: Cancer, online October 13, 2009.

RELATED STORIES:
Celecoxib May Help Prevent Colorectal Cancer In High Risk Patients   Different type of colon cancer vaccine reduces disease spread, Jefferson scientists show   Prostate irradiation raises risk of colon cancer   Colorectal cancer screening in Canada is cost-effective   People Who Exercise Lower Their Risk of Colon Cancer   Minimally Invasive Surgery Shown Safe and Effective Treatment for Rectal Cancer   Study examines quality of colonoscopy reporting and performance   Gallstones a risk factor for colon tumors   Many colon cancer patients skip follow-up care   No link seen between high-carb diet, colon cancer   Hispanics live in areas with limited capacity for colorectal cancer screening   City of Hope researchers to present rectal cancer, palliative care, benchmarking studies at ASCO   A gene for metastasis   Aspirin vs. colon cancer: study weighs benefits   Tests between colonoscopies could be lifesaver for high-risk patients   Higher Vitamin D Intake Needed to Reduce Cancer Risk   Protein Levels Indicate Risk of Death in Some Colorectal Cancer Patients   Discovery of a novel mechanism for the development of colon cancer   Study reveals differences in cancer stage presentation between rural and urban patients   Poor less likely to be screened for colon cancer   Mail and Electronic Reminders May Increase Colon Cancer Screening   Language a Barrier to Colorectal Cancer Screening in Mexican-Americans

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]